Abstract:We recently identified two virulence-associated small open reading frames (sORF) of Yersinia pestis , named yp1 and yp2 , and null mutants of each individual genes were highly attenuated in virulence. Plague vaccine strain EV76 is known for strong reactogenicity, making it not suitable for use in humans. To improve the immune safety of EV76, three mutant strains of EV76, Δ yp1 , Δ yp2 , and Δ yp1&yp2 were constructed and their virulence attenuation, immunogenicity, and protective efficacy in mice were evaluated. All mutant strains were attenuated by the subcutaneous ( s . c .) route and exhibited more rapid clearance in tissues than the parental strain EV76. Under iron overload conditions, only the mice infected with EV76Δ yp1 survived, accompanied by less draining lymph nodes damage than those infected by EV76. Analysis of cytokines secreted by splenocytes of immunized mice found that EV76Δ yp2 induced higher secretion of multiple cytokines including TNF-α, IL-2, and IL-12p70 than EV76. On day 42, EV76Δ yp2 or EV76Δ yp1&yp2 immunized mice exhibited similar protective efficacy as EV76 when exposed to Y . pestis 201, both via s . c . or intranasal ( i . n .) routes of administration. Moreover, when exposed to 200–400 LD 50 Y . pestis strain 201Δ caf1 (non-encapsulated Y . pestis ), EV76Δ yp2 or EV76Δ yp1&yp2 are able to afford about 50% protection to i . n . challenges, significantly better than the protection afforded by EV76. On 120 day, mice immunized with EV76Δ yp2 or EV76Δ yp1&yp2 cleared the i . n . challenge of Y . pestis 201- lux as quickly as those immunized with EV76, demonstrating 90–100% protection. Our results demonstrated that deletion of the yp2 gene is an effective strategy to attenuate virulence of Y . pestis EV76 while improving immunogenicity. Furthermore, EV76Δ yp2 is a promising candidate for conferring protection against the pneumonic and bubonic forms of plague. Y . pestis , the causative agent of the deadly plague, has caused three global pandemics throughout history and continues to pose a significant threat in various regions of the world. Unfortunately, there are currently no approved vaccines available to safeguard humans against Y . pestis infection. While the live-attenuated Y . pestis EV76 vaccine strain has been utilized in high-risk populations in China, Mongolia, and former Soviet countries, its usage is restricted due to potential severe adverse effects. In a recent study, we identified two small open reading frames (sORF)-encoded peptides of Y . pestis , namely SEP-yp1 and SEP-yp2, which are associated with the bacterium's virulence. To improve the safety and efficacy of the EV76 vaccine, we constructed three mutant strains (Δ yp1 , Δ yp2 , and Δ yp1&yp2 ) and evaluated their virulence attenuation, immunogenicity, and ability to protect against Y . pestis infection in mice. Our findings demonstrated that deleting the yp2 gene was a successful approach to diminish the virulence of Y . pestis EV76 while simultaneously enhancing its ability to provoke an immune response. Furthermore, our study revealed that EV76Δ yp2 exhibited superior protection against different forms of plague, including pneumonic and bubonic, making it a promising candidate for further development as a plague vaccine.

Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague

The Protective Effect of IL-17A in Pneumonic Plague Can Be Compensated by Effective Vaccines and Immunization Strategies in Mice

Complete Protection Against Yersinia pestis in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein via Aerosolized Intratracheal Inoculation

Relative Immunogenicity and Protection Potential of Candidate Yersinia Pestis Antigens Against Lethal Mucosal Plague Challenge in Balb/C Mice.

Sex-based difference in immune responses and efficacy of the pneumococcal conjugate vaccine

Combinatorial viral vector-based and live-attenuated vaccines without an adjuvant to generate broader immune responses to effectively combat pneumonic plague

Moderate Susceptibility to Subcutaneous Plague (Yersinia pestis) Challenge in Vaccine-Treated and Untreated Sonoran Deer Mice (Peromyscus maniculatus sonoriensis) and Northern Grasshopper Mice (Onychomys leucogaster)

Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague

Construction of a Live-Attenuated Vaccine Strain of Yersinia pestis EV76-B-SHUΔpla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation

Combination of live attenuated and adenovirus-based vaccines completely protects interferon gamma (IFNγ) knockout mice against pneumonic plague

A novel sORF gene mutant strain of Yersinia pestis vaccine EV76 offers enhanced safety and improved protection against plague

Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization

Pneumonic Plague Protection Induced by a Monophosphoryl Lipid A Decorated Yersinia Outer‐Membrane‐Vesicle Vaccine

Sex differences in vaccine induced immunity and protection against

Comparison of Immunological Responses of Plague Vaccines F1 + Rv270 and EV76 in Chinese-Origin Rhesus Macaque, Macaca Mulatta

Kinetics of Memory B Cell and Plasma Cell Responses in the Mice Immunized with Plague Vaccines

Evaluation of immunization protection efficacy of plague subunit vaccine]

A bacteriophage cocktail targeting Yersinia pestis provides strong post-exposure protection in a rat pneumonic plague model

A new generation needle- and adjuvant-free trivalent plague vaccine utilizing adenovirus-5 nanoparticle platform

Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium

Nasal immunization with plague F1-V recombinant protein mucosal vaccine induces systemic and mucosal immune responses in Balb/c mice